Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis
Clinical trial NCT02204397 · COMPLETED
Trial details
- NCT number
- NCT02204397
- Sponsor
- Jewish General Hospital
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-01
- Primary completion
- 2017-03-08
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.